Dexamethasone Acetate

Summary

Dexamethasone Acetate (CHEMBL1530428) is an approved small molecule; indicated across 5 conditions including plasma cell myeloma and leukemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 20
• Chemistry: 434.5 Da · C24H31FO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1530428
Name	Dexamethasone Acetate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	236702
Molecular formula	C24H31FO6
Molecular weight	434.5
InChIKey	AKUJBENLRBOFTD-RPRRAYFGSA-N

SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)F)C

IUPAC name: [2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate

Also known as: Decadron-la, Dectancyl, Dexamethasone acetate, Dexamethasone acetate anhydrous, Dexamethasone acetate monohydrate, Dexamethasoni acetas, Dexamethasoni acetas monohydrate, Fortecortin (crystal suspension), Neofordex, NSC-39471, SID855773, DEXAMETHASONE ACETATE

Patent coverage: 265 distinct patent families (821 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Survival motor neuron protein, Glucocorticoid receptor, Thromboxane A2 receptor, Nuclear receptor subfamily 1 group I member 2, Cannabinoid receptor 1, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HIF1A	8.1	Potency	7.9	nM	CHEMBL_ACT_4127824
HIF1A	8.1	Potency	7.9	nM	CHEMBL_ACT_4520433
NR3C1	7.85	AC50	14	nM	CHEMBL_ACT_25176119
SMN1	5.6	Potency	2512	nM	CHEMBL_ACT_3884100
Q9R1A7	5.35	EC50	4500	nM	CHEMBL_ACT_15463735

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	4	MONDO:0009693	EFO:0001378
leukemia	3	MONDO:0005059	EFO:0000565
acute pancreatitis	2	MONDO:0006515	EFO:1000652
lymphoma	1	MONDO:0005062	EFO:0000574
tooth disorder	0	MONDO:0006999	EFO:1001216

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
Not specified	5
PHASE3	4
PHASE2	4
PHASE4	3
PHASE1	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01550146	PHASE4	UNKNOWN	Single Dose of Dexamethasone in Femur Fractures
NCT02178449	PHASE4	UNKNOWN	Prolongation of Pain Free Time by the Use of Dexamethasone in Peripheral Nerve Blockade
NCT02588196	PHASE4	UNKNOWN	The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis
NCT00651261	PHASE3	UNKNOWN	Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01669499	PHASE3	COMPLETED	Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009
NCT01868269	PHASE3	COMPLETED	Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)
NCT01916252	PHASE3	COMPLETED	Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old
NCT06979596	PHASE2	RECRUITING	A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT00635154	PHASE2	COMPLETED	Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma
NCT01247961	PHASE2	WITHDRAWN	Early Treatment With Dexamethasone in Mild Acute Pancreatitis
NCT02419469	PHASE2	TERMINATED	Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT01421173	PHASE1	COMPLETED	Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
NCT05052970	PHASE1	UNKNOWN	Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
NCT01878708	EARLY_PHASE1	TERMINATED	A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
NCT02837614	EARLY_PHASE1	COMPLETED	Evaluation of Preoperative Submucosal Dexamethasone in Third Molar Surgery
NCT01169415	Not specified	WITHDRAWN	Effects of Steroid Tapering on Functional Capacity and Neurocognition
NCT01854515	Not specified	UNKNOWN	Comparison of Efficacy of Nebulizing Budesonide and Intravenous Dexamethasone Before Extubation on Prevention of Post-extubation Complications in Intensive Care Unit Patients
NCT02838719	Not specified	COMPLETED	Analgesic Efficacy of Dexamethasone in Different Routes of Administration in Transverse Abdominis Plane Block
NCT02855866	Not specified	COMPLETED	Interest of Cryotherapy or Cortisone Aerosol Therapy in Early Post-operative Swallowing Disorders Following Total Thyroidectomy
NCT02956070	Not specified	COMPLETED	Anti-inflammatory Steroids in the Prevention of Tooth Sensitivity

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).